Vanguard Personalized Indexing Management’s ADC Therapeutics ADCT Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.2K	Buy	+17,007	New	+$49.6K	﹤0.01%	2208

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Personalized Indexing Management's ADCT Position: Q2 2026 in Review

Vanguard Personalized Indexing Management opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 17,007 shares worth $18.2K. The stake represents ﹤0.01% of the portfolio and ranks #2208 among its holdings.

114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Vanguard Personalized Indexing Management held 17,007 shares of ADC Therapeutics worth $18.2K as of Q2 2026.
ADC Therapeutics was a new Vanguard Personalized Indexing Management position in Q2 2026.
ADC Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2208 holding.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.